Oncolytics Biotech Inc Stock: price and insider trades · United States

Oncolytics Biotech Inc is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 12 filings were filed, from 10 insiders.

No insider sold shares on the market over the period. Instead, the filings list 12 purchases totalling €258k, made by 10 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €89k, bought by Seizinger Bernd R. and made public on 20 January 2026. Those buying include 8 senior executives, 1 finance chief and 1 chief executive.

Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 12 filings, this issuer sits below that mark. Looking back to 2026, when coverage begins, insiders filed 12 purchases and no sales.

Within a 30-day window, 11 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 13 March 2026, 219 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4.

Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.